---
title: "Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296538977.md"
description: "Amylyx Pharmaceuticals priced a public offering of 14.09 million shares at $35.50, netting approximately $472 million. Proceeds will fund the U.S. launch of avexitide, manufacturing, R&D, and general corporate purposes. The underwriting agreement was signed on August 19, 2026, with closing expected on August 21, 2026."
datetime: "2026-08-20T21:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296538977.md)
  - [en](https://longbridge.com/en/news/296538977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296538977.md)
generator: "portal-rs"
---

# Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M

Amylyx Pharmaceuticals entered into an Underwriting Agreement for a public offering of 14,090,000 shares of common stock at $35.50 per share. The company expects net proceeds of approximately $471.7 million, or about $542.5 million if underwriters fully exercise a 30-day option to purchase up to 2,113,500 additional shares. Proceeds will support the potential U.S. launch of avexitide, manufacturing capacity, R&D, working capital and general corporate purposes. Closing is expected on August 21, 2026, subject to customary conditions.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for public offering of common stock
-   **Counterparty**: Leerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital, as representatives of the underwriters
-   **Signed / Effective**: Aug 19 2026 / same
-   **Duration / Termination**: Through closing on Aug 21 2026
-   **Reason**: Fund avexitide launch, R&D, and general purposes

Original SEC Filing: Amylyx Pharmaceuticals, Inc. \[ AMLX \] - 8-K - Aug. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock | AMLX Stock News](https://longbridge.com/en/news/296428560.md)
- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)
- [Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026](https://longbridge.com/en/news/296140552.md)
- [What does Europe’s AI lag mean for the region?](https://longbridge.com/en/news/296510589.md)
- [Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level](https://longbridge.com/en/news/296238728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**